 Adagio Therapeutics Inc. is set to go public Friday, after the upsized initial public offering of the Massachusetts-based biopharmaceutical company focused on antibody-based solutions for infectious diseases priced overnight at 17 a share, in the middle of the expected range. The company raised 309.4 million as it sold 18.2 million shares, up from expectations it would sell 17.7 million shares. 